Table 2.

Patient-reported outcomes (PROs)

Measure	Time point	n	Mean (SD)	p value		p value
				Paired t test	Non-parametric signed rank test	Mixed model analysis*
FACT/GOG-NTX †	Baseline	19	20.8 (9.6)	–	–	–
	4 weeks	18	16.7 (9.4)	0.0114	0.018	0.0263
	9 weeks	15	9.9 (5.6)	0.0009	<0.0001	<0.0001
	13 weeks	15	13.2 (8.5)	0.0007	<0.0002	<0.0001
BPI-SF ‡
Pain	Baseline	18	25.4 (18.5)	–	–	–
severity	4 weeks	18	18.2 (16.4)	0.0048	0.0052	0.0056
	9 weeks	16	15.1 (14.5)	0.0004	0.0001	<0.0001
	13 weeks	16	17.6 (16.6)	0.004	0.0007	<0.0001
Pain	Baseline	18	25.4 (18.5)	–	–	–
interference	4 weeks	18	18.2 (16.4)	0.0048	0.0052	0.0056
	9 weeks	16	15.1 (14.5)	0.0004	0.0001	<0.0001
	13 weeks	16	17.6 (16.6)	0.004	0.0007	<0.0001
Worst pain in	Baseline	18	6.2 (3.5)	–	–	–
last 24 hours	4 weeks	18	3.8 (2.7)	0.0057	0.0049	0.0004
	9 weeks	16	2.9 (2.1)	<0.0001	0.0002	<0.0001
	13 weeks	15	3.6 (2.5)	<0.0001	0.0006	<0.0001
FACT-G §
Physical	Baseline	18	9.2 (6.1)	–	–	–
Well-being	4 weeks	18	7.2 (5.6)	0.3	0.4	0.3
	9 weeks	14	5.0 (3.8)	<0.05	0.02	0.002
	13 weeks	16	5.5 (4.3)	0.01	0.002	0.0004
Social/family	Baseline	19	20.5 (6.3)	–	–	–
Well-being	4 weeks	16	19.7 (6.3)	0.7	0.8	0.4
	9 weeks	14	19.4 (8.5)	0.3	0.7	0.1
	13 weeks	15	19.6 (7.0)	0.3	0.6	0.3
Emotional	Baseline	19	5.3 (5.5)	–	–	–
Well-being	4 weeks	18	4.4 (4.0)	0.5	0.6	0.5
	9 weeks	16	3.8 (4.3)	0.4	0.3	0.2
	1 month	16	4.1 (3.9)	0.3	0.4	0.2
Functional	Baseline	19	20.8 (6.7)	–	–	–
Well-being	4 weeks	17	19.7 (8.4)	0.07	0.09	<0.05
	9 weeks	14	19.6 (7.0)	0.1	0.1	0.1
	1 month	15	20.4 (8.9)	0.4	0.4	0.3

*Mixed model analysis for time effect was performed for variables with four assessments.

^†Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Scale.

^‡Brief Pain Inventory – Short Form.

^§Functional Assessment of Cancer Therapy – General Scale.